Phenotypes Associated with This Genotype

Genotype
MGI:7496108

• Allelic Composition: Chd7^{tm2c(EUCOMM)Wtsi}/Chd7^{tm2c(EUCOMM)Wtsi}; Slc1a3^{tm1(cre/ERT2)Mgoe}/Slc1a3⁺
• Genetic Background: involves: 129S2/SvPas * C57BL/6 * C57BL/6N * SJL

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

nervous system

increased neuron apoptosis ( J:222062 )

• in the hippocampus at 12 weeks after tamoxifen treatment

abnormal neuronal stem cell morphology ( J:222062 )

• at 8 months after tamoxifen injection there is a significant depletion of neuronal stem cells

abnormal neuron number ( J:222062 )

decreased neuronal precursor cell number ( J:222062 )

• at 12 weeks after tamoxifen treatment a significant decrease in the number of neuronal progenitors and immature neurons

increased neuronal precursor cell number ( J:222062 )

• increase in the number of progenitors and immature neurons 4 weeks after tamoxifen injection

• at 12 weeks after tamoxifen treatment radial neuronal stem cells numbers are increased almost 3-fold and the number of proliferating radial neuronal stem cells is increased over 2-fold

decreased neuron number ( J:222062 )

• at 12 weeks and 8 months after tamoxifen treatment a significant decrease in the number of neuronal progenitors and immature neurons is seen

increased neuron number ( J:222062 )

• increase in the number of progenitors and immature neurons 4 weeks after tamoxifen injection

increased neuronal stem cell self-renewal ( J:222062 )

• increase in proliferation in the subgranular zone 6-7 days after following tamoxifen injection

cellular

increased neuron apoptosis ( J:222062 )

• in the hippocampus at 12 weeks after tamoxifen treatment

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
CHARGE syndrome		DOID:0050834	OMIM:214800	J:222062